drugset / Trial / NCT00134186

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

NCT00134186

Phase 2 Completed 43 enrolled Pharmacyclics LLC.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject motexafin gadolinium Diagnostic / imaging agent

Indications